by admin | Dec 16, 2021 | Press Releases
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. 
by admin | Feb 26, 2019 | Press Releases
Anaveon, an immuno-oncology company, today announced completion of a CHF 35 million Series A financing led by Syncona Ltd and joined by the Novartis Venture Fund. 
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022April 11, 2022
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022March 9, 2022
Anaveon to raise CHF 110 million in oversubscribed Series B financingDecember 16, 2021